Pegylated interferon‐α induced hypoferremia is associated with the immediate response to treatment in hepatitis C
John D. Ryan, Sandro Altamura, Emma Devitt, Sarah Mullins, Matthew W. Lawless, Martina U. Muckenthaler, John Crowe – 15 February 2012 – Pegylated interferon‐α (PEG‐IFN‐α) forms an integral part of the current treatment for hepatitis C virus (HCV) infection. PEG‐IFN‐α suppresses HCV production by augmenting the innate antiviral immune response. Recent studies have reported the induction of hepcidin, the iron regulatory hormone, by IFN‐α in vitro.